Stephen J.LurieMD, PhD, Senior Editor
To the Editor: Dr Yusuf and colleagues1 reported a reduction in the risk of developing diabetes during treatment with ramipril. However, examination of the data presented in Figure 1 reveals that the cumulative risk of developing diabetes in the placebo group at 2, 3, and 4 years of follow-up is approximately equal to the cumulative risk in the ramipril group at 3, 4, and 4.5 years, respectively. In other words, it appears that rather than preventing diabetes, treatment with ramipril only delays the recognition of diabetes by about 1 year.
Shlossberg AH. Ramipril and Risk of Diabetes. JAMA. 2002;287(2):186. doi:10.1001/jama.287.2.186-JLT0109-1-2
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: